The latest quotation and drug purchase guide of erdafitinib in 2024

Erdafitinib (Erdafitinib), as an innovative oral targeted drug, is designed to treat specific types of advanced or metastatic urothelial cancer. Its mechanism of action is to inhibit the activity of the FGFR receptor family, thereby controlling the growth and spread of tumor cells. FGFR, or fibroblast growth factor receptor, plays a key role in cell proliferation and angiogenesis.

Currently, erdafitinib is not yet on the market in China. Therefore, if domestic patients need the drug, they need to purchase it through foreign channels. Among them, the Hong Kong version of the original drug is more expensive, about more than 20,000 yuan, and can be obtained through Hong Kong pharmacies. In comparison, the prices of foreign generic drugs are more affordable, such as the Laos version and the Bangladesh Yaopin International version, with prices ranging from a few hundred yuan to more than 2,000 yuan. It is worth noting that these generic drugs are basically the same as the original drugs in terms of pharmaceutical ingredients.

Advanced urothelial cancer is a difficult-to-treat cancer that is often not detected in its early stages, resulting in most patients being diagnosed in the late stages of the cancer. At this point, treatment options become relatively limited, and traditional chemotherapy and radiotherapy are often ineffective and may cause significant side effects.

The specificity of erdafitinib makes it ideal for the treatment of patients with advanced urothelial cancer who have FGFR genetic abnormalities, including mutations or copy number gains. By precisely targeting this molecular pathway, erdafitinib has been shown to be more efficient in inhibiting tumor growth, resulting in better efficacy and better patient tolerance than traditional treatments.

However, like other drugs, erdafitinib may also cause a series of side effects, such as fatigue, nausea, diarrhea and other common symptoms, as well as high blood pressure, visual impairment and other potentially more serious adverse reactions. Therefore, before initiating treatment with erdafitinib, physicians will conduct a thorough patient assessment to ensure the safety and effectiveness of the treatment.